Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Quality of Life and Patient‐Reported Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis

Randomised evidence suggests SGLT2 inhibitors enhance EQ-5D Index score, diabetes-specific QoL and several PROs in T2DM, particularly in physical, emotional and treatment satisfaction domains, supporting their earlier use in this population.